In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
Veranstaltungsempfehlung: 12. Klinische Pharmazie-Update-Seminar, 10. und 11. September 2021, Wiesbaden
A pooled analysis on therapy response and prognosis of patients with low HR-positive, HER2-negative early breast cancer has been published in European Journal of Cancer
We are happy to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Annual Meeting 2021, which will take place from 4 to 8 June.
The International Immuno-Oncology Biomarker Working Group has launched a global survey on the potential use of Tumor Infiltrating Lymphocytes (TILs) for future trial designs and use in daily practice.
We are delighted to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2021, which will take place from 5 to 8 May 2021.
We are delighted to inform you that the first results of the randomized phase III PenelopeB trial have been published on a Rapid Communications basis in Journal of Clinical Oncology.
An analysis including breast cancer patients with brain metastases from the BMBC registry has been published in Cancers
Registration for the ESMO Breast Cancer Virtual Meeting, taking place 5-8 May 2021 is now open.
Wir danken den Referenten, Teilnehmern und Organisatoren für das tolle virtuelle Jahrestreffen. Die Präsentationen finden Sie auf unserer Website zum Download und als Video zum Nachhören.
The 17th St.Gallen International Breast Cancer Conference is going fully virtual!
A translational research project investigating genomic patterns of mutational signatures in breast cancer patients from GeparSepto trial has been published in Annals of Oncology.
We are delighted to inform you that final results of the first randomized phase II MALE trial have been published in JAMA Oncology.
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
GBG Jahrestreffen vom 24. bis 26. Februar 2021 wissenschaftliche Veranstaltung
A retrospective analysis investigating the effect of germline BRCA1/2 mutations on severe haematological toxicities in TNBC patients treated with chemotherapy has been published in European Journal of Cancer.
A new consortium of the EU Innovative Medicines Initiative (IMI) will establish the biggest database of pathology images to accelerate the development of artificial intelligence in medicine.
Entscheidungshilfen zur Durchführung einer COVID-19-Impfung bei Studienpatienten.
Save the date: Virtuelles State of the Art Meeting am 27. Februar.
A translational research project evaluating effect of chemotherapy on different immune subsets in TNBC patients from GeparNuevo trial was published in Journal for ImmunoTherapy of Cancer
Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.